28/04/2021 · UCB Announces PDUFA Date for Bimekizumab. Brussels, Belgium – 28 April 2021, 7:00 CEST – UCB announced today that the Food and Drug Administration (FDA) has set the Prescription Drug User Fee Act (PDUFA) date for UCB's Biologics License Appliion (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque ...